دورية أكاديمية

Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

التفاصيل البيبلوغرافية
العنوان: Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
المؤلفون: Díaz González, Álvaro, Hernández Guerra, Manuel, Pérez Medrano, Indhira, Sapena, Víctor, Riveiro Barciela, Mar, Barreira Díaz, Ana, Gómez, Elena, Morillas, Rosa M., Barrio, María del, Escudé, Laia, Mateos, Beatriz, Horta, Diana, Gómez, Judith, Conde, Isabel, Ferre Aracil, Carlos, El Hajra, Ismael, Arencibía, Ana, Zamora, Javier, Fernández, Ainhoa, Salcedo, Magdalena, Molina, Esther, Soria, Anna, Estévez, Pamela, López, Carmen, Álvarez Navascúes, Carmen
المصدر: Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
بيانات النشر: Wolters Kluwer Health
المجموعة: Dipòsit Digital de la Universitat de Barcelona
مصطلحات موضوعية: Hepatitis, Malalties autoimmunitàries, Autoimmune diseases
الوصف: In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options.
نوع الوثيقة: article in journal/newspaper
وصف الملف: 39 p.; application/pdf
اللغة: English
تدمد: 1527-3350
العلاقة: Versió postprint del document publicat a: https://doi.org/10.1097/hep.0000000000000018Test; Hepatology, 2023, vol. 77, num. 4, p 1095-1105; https://doi.org/10.1097/hep.0000000000000018Test; http://hdl.handle.net/2445/203780Test
الإتاحة: https://doi.org/10.1097/hep.0000000000000018Test
http://hdl.handle.net/2445/203780Test
حقوق: (c) American Association for the Study of Liver Diseases, 2023 ; info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.A7E4950A
قاعدة البيانات: BASE